Abstract:Objective: This study aimed to evaluate the diagnostic value of combining ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing in ovarian tumors. Methods: Sixty-four patients suspected of having ovarian tumors, admitted to our hospital from July 2021 to July 2023, were selected for the study. All patients underwent ultrasound-guided percutaneous biopsy and serum tumor markers CA125 and CEA level testing. Surgical pathology results were used as the gold standard for comparison. The diagnostic performance of ultrasound-guided percutaneous biopsy alone, serum CA125, serum CEA, and their combination were evaluated. Receiver operating characteristic (ROC) curve analysis was performed, and the sensitivity, specificity, and accuracy were calculated. The differences in diagnostic performance were compared using the chi-square test, with a P < .05 considered statistically significant. Results: The results of this study demonstrate that combining ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing significantly improved the diagnostic accuracy for ovarian tumors compared to individual testing modalities. Surgical pathology, the gold standard, confirmed 52 malignant and 12 benign tumors among the 64 patients examined. When evaluated individually, the concordance rate between ultrasound-guided biopsy and surgical pathology was 90.63%, while serum CA125 and CEA had diagnostic accuracies of 73.44% and 64.06%, respectively. However, when the two serum markers were used in combination, the diagnostic accuracy increased to 81.25%. Notably, the integration of ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing produced the highest diagnostic accuracy at 95.31%. Statistical analysis confirmed this combined approach had significantly better accuracy, sensitivity, and specificity compared to individual tests (P < .05). ROC curve analysis further substantiated the superior diagnostic value of this integrated testing strategy. Conclusion: The findings of this study demonstrate that the integration of ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing markedly enhances diagnostic accuracy for ovarian tumors, with a combined accuracy exceeding 95%. This integrated diagnostic protocol represents a robust and clinically valuable approach that should be more widely adopted to improve early detection and optimize the management of ovarian neoplasms. The implementation of this combined testing strategy has the potential to significantly impact clinical decision-making and patient outcomes in the diagnosis and treatment of ovarian tumors.

The application value of two-dimensional ultrasound combined with contrast-enhanced ultrasound in the differential diagnosis of benign, borderline, and malignant ovarian epithelial tumors

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Value of Scoring by Contrast-Enhanced Ultrasound Combined with Ultrasonic Elastography in Differential Diagnosis of BI-RADS 4 Lesions

Application value of color doppler ultrasound and ultrasound contrast in the differential diagnosis of ovarian tumor

Comparison of Contrast-Enhanced Ultrasound, IOTA Simple Rules and O-RADS for Assessing the Malignant Risk of Sonographically Appearing Solid Ovarian Masses.

Contrast-enhanced ultrasound combined with Ovarian-Adnexal Reporting and Data System US risk stratification and management system for diagnosis of adnexal masses

Differentiating Benign From Malignant Ovarian Masses With Solid Components: Diagnostic Performance of CEUS Combined With IOTA Simple Rules and O-RADS

Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma

Diagnostic Efficiency of Gynecologic Imaging Reporting and Data System Combined With 3-dimensional Contrast-enhanced Ultrasound Scoring System in Evaluating Ovarian Tumor

Clinical value of quantitative analysis of contrast-enhanced ultrasonography in the differential diagnosis of benign and malignant pelvic tumors

Application of CT Scan in Diagnosis of Pathological Type and Origin of Metastatic Ovarian Tumors

The Application Value of Contrast-Enhanced Ultrasound in Testicular Occupied Lesions

Ultrasound-Guided Percutaneous Biopsy Combined Serum CA125, CEA Level Examination in the Diagnosis of Ovarian Tumors Value Analysis

Analysis and Evaluation of Ultrasound Imaging Features and Pathological Results of Ovarian Cancer

An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors

Application Value of Contrast-Enhanced Ultrasound in the Diagnosis of Intermediate Trophoblastic Tumours

Diagnostic Value of Contrast‐Enhanced Ultrasound in Benign and Malignant Adnexal Masses

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors

Ultrasonography diagnosis of ovarian surface serous papillary cystadenocarcinoma

Application of real-time ultrasound elastography for discrimination of low- and high-grade serous ovarian carcinoma.